ho says no to a $10,000 watch? Are there second acts in Big Pharma? And what’s it like to climb Mount Everest?
We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation on biotech’s little-discussed war for talent, which is lining the pockets of the few people who actually know how to make next-generation treatments. Then we talk to Dr. Gary Nabel, chief scientific officer at Sanofi, about how the company plans to make up lost ground in the lucrative field of oncology. Finally, biotech journalist Luke Timmerman joins us to detail his trip to the top of Everest and we run through a lightning round on Hong Kong IPOs, unicorn staffing problems, and a pioneering FDA decision.